Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > this is what a good bio therapeutic

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Apr 27, 2022 2:13pm

143 Views

Post# 34636327

this is what a good bio therapeutic

company should look like (my best kept secret still time to get in guys) LYRA

Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	Volume or Value	Price
Apr 14/22	Apr 12/22	Perceptive Advisors Llc	Indirect Ownership	Common Stock	P - Open market or private purchase	5,924,170	$4.22
Apr 14/22	Apr 12/22	Nbvm Gp, Llc	Indirect Ownership	Common Stock	P - Open market or private purchase	765,010	$4.22
Apr 14/22	Apr 12/22	Nbvm Gp, Llc	Indirect Ownership	Common Stock	P - Open market or private purchase	527,806	$4.22
Apr 14/22	Apr 12/22	Nbvm Gp, Llc	Indirect Ownership	Common Stock	P - Open market or private purchase	1,076,851	$4.22
Apr 14/22	Apr 12/22	Anderson Edward T	Direct Ownership	Common Stock	P - Open market or private purchase	118,483	$4.22
Apr 14/22	Apr 12/22	Anderson Edward T	Indirect Ownership	Common Stock	P - Open market or private purchase	765,010	$4.22
Apr 14/22	Apr 12/22	Anderson Edward T	Indirect Ownership	Common Stock	P - Open market or private purchase	527,806	$4.22
Apr 14/22	Apr 12/22	Anderson Edward T	Indirect Ownership	Common Stock	P - Open market or private purchase	1,076,851	$4.22
Apr 13/22	Apr 12/22	Waksal Harlan	Direct Ownership	Common Stock	P - Open market or private purchase	236,966	$4.22